In response to the ongoing pandemic of COVID-19, the University of Hong Kong (HKU) has extended its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate a nasal spray COVID-19 vaccine made with live attenuated influenza viral vector. The effort is led by the State Key Laboratory for Emerging Infectious Diseases (SKL) at HKU.